{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:49:10Z","timestamp":1788544150167,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long\u2010term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase\u2013to\u2013platelet ratio index (APRI) and Fibrosis\u20104 index (FIB\u20104) scores remain unknown. The purpose of the present study was to assess DAA's long\u2010term benefits, including frequencies of posttreatment week 96 ALT\/AST\u2009&lt;\u200930 (males)\/19 (females) (&lt;30\/19), improvement of APRI and FIB\u20104 scores, and the associated factors. This was a single\u2010center, retrospective study on 157 patients with HCV with DAA\u2010mediated sustained virological response (SVR) 12. At posttreatment week (post\u2010Rx wk) 96, 75.4% had ALT\u2009&lt;\u200930\/19; 62.7%, AST\u2009&lt;\u200930\/19; and 60.1%, both ALT\/AST\u2009&lt;\u200930\/19. ALT\/AST\u2009&lt;\u200930\/19 at post\u2010Rx wk 96 was associated with ALT\/AST\u2009&lt;\u200930\/19 at post\u2010Rx wk 12 (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.026), independently of Child\u2010Turcotte\u2010Pugh\u2009&lt;\u20096 (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.862), platelets\u2009\u2264\u2009120\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.343). Improvement rates of APRI\u2009&lt;\u20090.5 and FIB\u20104\u2009&lt;\u20091.45 from baseline to post\u2010Rx wk 96 were from 30.9% to 80.5%, and from 23% to 37.8%, respectively. Both APRI and FIB\u20104 improvement was associated with both ALT\/AST\u2009&lt;\u200930 (males)\/19 (females) at post\u2010Rx wk 12 (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.012 and 0.011, respectively). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: The present study showed that DAA\u2010mediated SVR12 in patients with HCV resulted in (1) high and durable rates of ALT (75.4%), AST (62.7%), and both ALT\/AST (60.1%)\u2009&lt;\u200930\/19, and (2) high rates of APRI\u2009&lt;\u20090.5 (80.5%) and FIB\u20104\u2009&lt;\u20091.45 (37.8%) at post\u2010Rx wk 96, demonstrated clinical value of ALT\/AST\u2009&lt;\u200930\/19 and excellent long\u2010term outcomes of DAA\u2010mediated SVR12 in these patients.<\/jats:p>","DOI":"10.1002\/hep4.2098","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:44:37Z","timestamp":1665553477000},"page":"3496-3504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30\/19 criteria and improved APRI and FIB\u20104 scores"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-5513","authenticated-orcid":false,"given":"Tung","family":"Huynh","sequence":"first","affiliation":[{"name":"Department of Pharmacy,University of California Irvine Health,Orange,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ma","sequence":"additional","affiliation":[{"name":"California University of Science and Medicine,School of Medicine,Colton,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke\u2010Qin","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,University of California Irvine, School of Medicine,Orange,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"hep42098-bib-0002-20241116","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14656566.2019.1697674","article-title":"Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment for Hepatitis C","volume":"21","year":"2020","journal-title":"Expert Opin Pharmacol"},{"key":"hep42098-bib-0004-20241116","article-title":"Direct\u2010acting antivirals for chronic hepatitis C","volume":"9","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"hep42098-bib-0005-20241116","first-page":"258","article-title":"Hepatitis C virus clearance by direct acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminotransferase normalization","volume":"6","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"hep42098-bib-0006-20241116","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/jhep.2003.50344","article-title":"Dynamics of alanine aminotransferase during hepatitis C treatment","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep42098-bib-0007-20241116","first-page":"117","article-title":"The de ritis ratio: the test of time","volume":"34","year":"2013","journal-title":"Clin Biochem Rev"},{"key":"hep42098-bib-0008-20241116","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/liv.13705","article-title":"Serum alanine aminotransferase level and liver\u2010related mortality in patients with chronic hepatitis B: a large national cohort study","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"hep42098-bib-0009-20241116","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple non\u2010invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep42098-bib-0010-20241116","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep42098-bib-0011-20241116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajg.2017.05.005","article-title":"APRI test and hyaluronic acid as non\u2010invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta\u2010analysis","volume":"18","year":"2017","journal-title":"Arab J Gastroenterol"},{"key":"hep42098-bib-0012-20241116","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase\u2010to\u2010platelet ratio index for the staging of hepatitis C\u2010related fibrosis: an updated meta\u2010analysis","volume":"53","year":"2011","journal-title":"Hepatology"},{"key":"hep42098-bib-0013-20241116","doi-asserted-by":"crossref","first-page":"661","DOI":"10.21037\/hbsn.2020.01.05","article-title":"FIB\u20104 score and hepatocellular carcinoma risk after hepatitis C virus cure time to revise surveillance?","volume":"9","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"hep42098-bib-0014-20241116","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB\u20104: an expensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep42098-bib-0015-20241116","first-page":"1","article-title":"Real\u2010world single center experience with direct acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment","volume":"28","year":"2020","journal-title":"Antiviral Chem Chemother"},{"key":"hep42098-bib-0016-20241116","article-title":"FIB\u20104 regression with direct\u2010acting antiviral therapy in patients with hepatitis C infection: a safety\u2010net hospital experience","volume":"7","year":"2020","journal-title":"Front Med"},{"key":"hep42098-bib-0017-20241116","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","year":"1981","journal-title":"Hepatology"},{"key":"hep42098-bib-0018-20241116","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","year":"1994","journal-title":"Hepatology"},{"key":"hep42098-bib-0019-20241116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","year":"2002","journal-title":"Ann Intern Med"},{"key":"hep42098-bib-0020-20241116","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1478-3231.2007.01519.x","article-title":"Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B","volume":"27","year":"2007","journal-title":"Liver Int"},{"key":"hep42098-bib-0021-20241116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1155\/2008\/213897","article-title":"Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?","volume":"22","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"hep42098-bib-0022-20241116","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/jhep.2003.50344","article-title":"Dynamics of alanine aminotransferase during hepatitis C virus treatment","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep42098-bib-0023-20241116","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.3748\/wjg.v19.i46.8678","article-title":"Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"hep42098-bib-0024-20241116","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10620-020-06286-3","article-title":"Excellent safety and sustained virologic response to direct\u2010acting antivirals treatment in HCV\u2010infected geriatric patients: a real\u2010world data","volume":"66","year":"2021","journal-title":"Dig Dis Sci"},{"key":"hep42098-bib-0025-20241116","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver\u2010enzyme results in asymptomatic patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"hep42098-bib-0026-20241116","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/gast.1996.v110.pm8536854","article-title":"Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection","volume":"110","year":"1996","journal-title":"Gastroenterology"},{"key":"hep42098-bib-0027-20241116","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","year":"1999","journal-title":"Hepatology"},{"key":"hep42098-bib-0028-20241116","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2169\/internalmedicine.49.2653","article-title":"Re\u2010evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients","volume":"49","year":"2010","journal-title":"Intern Med"},{"key":"hep42098-bib-0029-20241116","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0016-5085(88)80022-2","article-title":"Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis","volume":"95","year":"1988","journal-title":"Gastroenterology"},{"key":"hep42098-bib-0030-20241116","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep42098-bib-0031-20241116","first-page":"222","article-title":"Indirect serum fibrosis markers in hepatitis C virus (HCV) infection","volume":"66","year":"2012","journal-title":"Med Arh"},{"key":"hep42098-bib-0032-20241116","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct\u2010acting antiviral agents","volume":"19","year":"2019","journal-title":"BMC Gastroenterol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T06:01:13Z","timestamp":1731736873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2098","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"2022-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}